Skip to main content
. 2019 Aug 18;5(2):e000990. doi: 10.1136/rmdopen-2019-000990

Figure 2.

Figure 2

Proportions of patients with (A) complete resolution of enthesitis and (B) complete resolution of dactylitis at week 24 among patients who were TNF-naïve, MTX-naïve and TNF-naïve, and csDMARD-naïve and TNF-naïve. csDMARD, conventional synthetic disease-modifying antirheumatic drug; MTX, methotrexate; TNF, tumour necrosis factor.